In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthofix Spin-Out Presents Another Opportunity For Private Equity

Executive Summary

A handful of orthopedic companies are combating sluggish markets by sticking with what they know best – selling hip and knee implants. This has created a robust opportunity for private equity investors looking to build businesses in orthopedics peripheral markets. Health care-focused PE firm Water Street Healthcare Partners last month made the latest move by agreeing to buy Breg Inc., the sports medicine business of Orthofix International NV, for $157.5 million or 1.5 times 2011 revenues of $103 million.

You may also be interested in...



Water Street: Finding a Middle-Market PE Niche

While many private equity investors appear to be focusing on the high and low ends of the device investment spectrum, Chicago-based Water Street Healthcare Partners is a firm carving its niche out of middle-market opportunities.

Stryker Sells Physical Therapy Business To Private Equity Firm For $150 Mil.

Stryker is getting out of the physical therapy business to focus on its core orthopedic franchise

China-US Divide Deepens On Covid Vaccines, Azar Taiwan Visit

China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel